Please Wait

Applying Filters...

Excipient Market Overview: Evonik launches high-purity excipients; India mandates disclosures from March 2026

Data Compilation
#PharmaFlow

Pipeline Prospector October 2025: Novartis to buy Avidity for US$ 12 bn; FDA approves Bayer’s med to treat hot flashes

Stock Recap
#PipelineProspector

Cefotaxime Sodium

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

41 API Suppliers, 14 USDMF, 17 CEP/COS, 1 JDMF, 5 EU WC, 7 KDMF, 1 NDC API, 23 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

2 Intermediate Suppliers

2 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

275 FDF Dossiers, 40 FDA Orange Book, 115 Europe, 2 Canada, 27 South Africa, 91 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 10GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 6 News #PharmaBuzz

GLOBAL SALES INFORMATION

54 Regulatory FDF Prices

54 Regulatory FDF Prices

MARKET PLACE

22 APIs, 10 FDF Dossiers

REF. STANDARDS & IMPURITIES

3 EDQM, 4 Others

$ Xls download

Filters

Log in to download the data

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	MF Registration No.	Classification	Initial Date of Reg.	Latest Date of Reg.	Registrant's Address
31/10/2025	Hanmi Pharmaceutical	South Korea	HANMI FINE CHEMICAL CO. , LTD.	224MF10209	Sterile cefotaxime sodium	2012-10-29	2013-10-23	57, Gyeongje-ro, Siheung-si, Gyeonggi-do, Korea

Contact us
to update this info

Cefotaxime Sodium

Cefotaxime Sodium

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

41 API Suppliers

14 USDMF

17 CEP/COS

1 JDMF

5 EU WC

7 KDMF

1 NDC API

23 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

INTERMEDIATES

2 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

275 FDF Dossiers

40 FDA Orange Book

115 Europe

2 Canada

27 South Africa

91 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 10GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

DIGITAL CONTENT

1 Data Compilation #PharmaFlow

6 News #PharmaBuzz

GLOBAL SALES INFORMATION

54 Regulatory FDF Prices

MARKET PLACE

22 APIs

10 FDF Dossiers

REF. STANDARDS & IMPURITIES

3 EDQM

4 Others

Filters

INJECTABLE;INJECTION - EQ 10GM BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - EQ 1GM BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - EQ 2GM BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - EQ 500MG BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons